Sugi Predict

Sugi Predict / Compounds / SCHEMBL2495592

SCHEMBL2495592

SCHEMBL2495592

CCOC(=O)c1cc(C)c(C=O)[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 1/20 0.53
▸ ALDH1A1 P00352 6/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ POLB P06746 1/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ HPGD P15428 4/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ RAB9A P51151 3/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ LMNA P02545 3/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ GAA P10253 2/20 0.47
▸ GLA P06280 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16569634 0.84 ALDH1A1 (0.48) KDRALDH1A1KMT2APOLBSMN1; SMN2
SCHEMBL4475926 0.83 CYP1A2 (0.51) KDRALDH1A1POLBKDM4ERAB9A
SCHEMBL3591851 0.81 KDR (0.49) KDRALDH1A1KMT2ASMN1; SMN2HPGD
SCHEMBL11997345 0.81 KDR (0.49) KDRALDH1A1KMT2ASMN1; SMN2HPGD
SCHEMBL3591855 0.81 KDR (0.49) KDRALDH1A1KMT2ASMN1; SMN2HPGD
SCHEMBL7559710 0.79 ALDH1A1 (0.47) ALDH1A1KMT2APOLBSMN1; SMN2HPGD
SCHEMBL2150729 0.79 ALDH1A1 (0.53) ALDH1A1KMT2APOLBSMN1; SMN2HPGD
SCHEMBL11191069 0.77 CYP1A2 (0.55) ALDH1A1KMT2ASMN1; SMN2HPGDKDM4E
SCHEMBL4465333 0.77 ALDH1A1 (0.44) ALDH1A1KMT2ASMN1; SMN2HPGDKDM4E
SCHEMBL3281546 0.77 SMN1; SMN2 (0.50) ALDH1A1KMT2APOLBSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024105563-A1 SUBSTITUTED BICYCLIC PYRIDONE DERIVATIVES PFIZER INC. (US) 2024-05-23 — — WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
US-20220289727-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-09-15 — — US disclosed
EP-4017850-A1 ENZYME INHIBITORS Kalvista Pharmaceuticals Limited (GB) 2022-06-29 — — EP disclosed
CN-114258392-A Enzyme inhibitors 卡尔维斯塔制药有限公司 2022-03-29 — — CN disclosed
WO-2021032935-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-25 — — WO disclosed
WO-2021032935-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-25 — — WO disclosed
WO-2021032938-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-25 — — WO disclosed
WO-2021032938-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-25 — — WO disclosed
US-20190241569-A1 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER BOSTON BIOMEDICAL INC (US) 2019-08-08 — — US disclosed
EP-1255752-A2 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS Sugen, Inc. (US) 2002-11-13 — — EP disclosed
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PHARMACIA & UPJOHN COMPANY LLC 2002-10-24 — — US disclosed
WO-2002081466-A1 PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES SUGEN, INC. (US) 2002-10-17 — — WO disclosed
EP-1244672-A1 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS Sugen, Inc. (US) 2002-10-02 — — EP disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 — — WO disclosed
EP-1139754-A1 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY Sugen, Inc. (US) 2001-10-10 — — EP disclosed
WO-2001060814-A2 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 2001-08-23 — — WO disclosed
WO-2001049287-A1 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY SUGEN, INC. (US) 2001-07-12 — — WO disclosed
WO-2001046196-A1 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 2001-06-28 — — WO disclosed
WO-2000038519-A1 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY SUGEN, INC. (US) 2000-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289727-A1 ENZYME INHIBITORS SERPINB1, ACE, GAA KDR 4240/4885ALDH1A1 237/4885KMT2A 2768/4885
US-20190241569-A1 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER MAP3K2, MAP3K1, MAP3K3 KDR 484/4885ALDH1A1 880/4885KMT2A 715/4885
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 KDR 1372/4885ALDH1A1 2793/4885KMT2A 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.